|
Match
|
Document |
Document Title |
|
|
5362489 |
Use of recombinant B-cell differentiation factor for augmenting antibody production and stimulating bone marrow proliferation
A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA,...
|
|
|
5362490 |
Human myelomonocyte interferon-gamma, and process for preparation and use thereof
The present invention relates to a novel human interferon-gamma derived from an established human myelomonocyte, a process to prepare said interferon-gamma, and its use. The human myelomonocyte...
|
|
|
5359034 |
Cysteine depleted IL-6 muteins
Muteins of IL-6 and truncated IL-6 are prepared by recombinant DNA techniques. In the muteins, the cysteine residues that occur at positions, or at positions corresponding to positions, 45 and 51...
|
|
|
5348729 |
Evaluative means for detecting inflammatory reactivity
The present invention is directed to a method for testing the susceptibility of a mammal to inflammatory diseases which comprises the steps of: administering to a mammal a compound selected from...
|
|
|
5346696 |
Asialoglycoprotein - conjugated medicinal agent
The present invention relates to a conjugated medicinal agent prepared by combining asialoglycoprotein with a medicine which acts specifically on the liver. The conjugated medicinal agent of the...
|
|
|
5312621 |
Method of treating fibrotic disorders
A novel method of treating fibrotic disorders in humans comprises the administration of a sufficient quantity of a composition containing a human alpha- or beta-interferon to raise the total...
|
|
|
5310550 |
Method of treating thrombocytopenia using human BCDF in combination with IL-3
Thrombocytopenia is treated by administering a subject suffering from thrombocytopenia a composition containing human B cell differentiation activity in combination with IL-3.
|
|
|
5271931 |
Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
The present invention relates to the use of interferon and/or interleukin-6 to increase intravascular C1 inhibitor concentrations in patients exhibiting or at risk for a C1 inhibitor deficiency....
|
|
|
5270037 |
Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections
The use of pharmaceutical compositions comprising at least one antimalarial active substance and an interferon, preferably interferon-gamma (IFN-γ), is disclosed. The pharmaceutical composition...
|
|
|
5244655 |
Process for the purification of recombinant human beta interferon, beta interferon thus purified and pharmaceutical compositions which contain it
A process is described for the purification of recombinant human beta interferon which comprises the use of three chromatographic stages carried out in series, utilizing as stationary phases: glass...
|
|
|
5234684 |
Method for the prevention and treatment of bovine mastitis
A method for treating or preventing mastitis in cows is disclosed. The method contemplates the intramammary injection of bovine interferon-gamma. Interferon-gamma can be administered prior to...
|
|
|
5230886 |
Tumor cell suppression
A method for treating a cancer includes administration of an endotoxin to a patient at least a portion of whose neoplastic cells express the CD14 surface receptor. The endotoxin can be administered...
|
|
|
5215744 |
Methods for the treatment of tumors
Disclosed is a method of treating tumors capable of being treated with interferon by administering interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts sufficient...
|
|
|
5211945 |
Compositions and methods for modulating the effect of TNF and IL-1
This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines. In case of deleterious effects, the invention...
|
|
|
5183746 |
Formulation processes for pharmaceutical compositions of recombinant β -
Stable pharmaceutical compositions suitable for parenteral administration to animals or humans are prepared comprising a therapeutically effective amount of a recombinant IFN-β protein dissolved...
|
|
|
5141735 |
Substituted amino-benzodiazepines having anitviral activity
Novel substituted 2-amino-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepines and compositions containing same for treatment and prophylaxis of viral infections, including HIV infections.
|
|
|
5122368 |
Anthracycline conjugates having a novel linker and methods for their production
The invention relates to anthracycline conjugates comprising at least one anthracycline molecule linked to a molecule that is reactive with a cell population to be eliminated such as antibody,...
|
|
|
5116943 |
Oxidation-resistant muteins of Il-2 and other protein
A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine...
|
|
|
5114711 |
Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates
Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides...
|
|
|
5104653 |
Use of human interferon-beta for stimulation of erythropoiesis
Interferon-beta, preferably in low doses, is used for stimulation of erythropoiesis in disorders characterized by lack of maturation of progenitor blood cells to red cells.
|
|
|
5059418 |
Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
A method of treating patients having viral infections exhibiting a synergistic antiviral effect in combination therapy of viral infections is comprised of combining synergistically effective...
|
|
|
5055289 |
Interferon antibody therapeutic compositions having an extended serum half-life
A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the...
|
|
|
RE33653 |
Human recombinant interleukin-2 muteins
Muteins of biologically active proteins such as IFN-β and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to...
|
|
|
5026544 |
Methods and compositions for inhibiting the growth of neoplastic cells
The present disclosure is directed to the use of combinations of a papaverine family member agent together with an interferon for the treatment of proliferative disorders such as neoplasias and...
|
|
|
5019382 |
Treatment of immuno-resistant disease with low-dose interferon
Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of...
|
|
|
5017371 |
Method for reducing side effects of cancer therapy
Low doses of interferon contacted with the oral and pharyngeal mucosa of a patient in conjunction with administration of radiation therapy or chemotherapy reduces the toxic side effects associated...
|
|
|
5015730 |
Preparation of homogeneous human fibroblast interferon
Human fibroblast interferon has been purified to homogeneity by use of a novel procedure combining affinity chromatography and high pressure liquid chromatography (HPLC).
|
|
|
5004605 |
Low pH pharmaceutical compositions of recombinant β-interferon
Stable pharmaceutical compositions suitable for parenteral administration to mammals are prepared which are in a pH range of about 2 to about 4 and comprise a therapeutically effective amount of a...
|
|
|
4997645 |
Methods and pharmaceutical composition for the treatment of tumors
Disclosed is a method of treating tumors capable of being treated with interferon which is comprised of interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts...
|
|
|
4994556 |
Novel lymphokine and its production and uses
A novel lymphokine and its production and uses are disclosed. The lymphokine is a glycoprotein with a molecular weight of 15,000±2,000 daltons; isoelectric point pI, 4.5±0.5; electrophoretic...
|
|
|
4992271 |
Formulation for lipophilic IL-2 proteins
An improved process for recovering and purifying lipophilic recombinant proteins such as human β-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated...
|
|
|
4980161 |
Method of treating viral infection in plants
There is disclosed a method of treating or preventing viral infections in plants wherein an animal interferon is applied to the plants.
|
|
|
4962207 |
Organic derivatives of tellurium and selenium
The present application discloses novel potassium salts of particular tellurium and selenium compounds which are useful for the stimulation of the production of cytokines.
|
|
|
4962091 |
Controlled release of macromolecular polypeptides
An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.
|
|
|
4961969 |
Process for recovering microbially produced interferon-β
An approved procedure for the purification and renaturation of biologically active, bacterially produced IFN-β is described. The partially purified material obtained by solubilization of isolated...
|
|
|
4959314 |
Cysteine-depleted muteins of biologically active proteins
Muteins of biologically active proteins such as IFN-β and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to...
|
|
|
4957733 |
Pharmaceutical products
Pharmaceutical product comprising an interferon and a compound of formula (A) ##STR1## or a pro-drug, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative or either of the...
|
|
|
4911908 |
Interferon administration vehicles
An interferon preparation to be administered topically is provided comprising: (a) a therapeutically effective amount of one or more interferons; (b) a vehicle base compatible with the interferon...
|
|
|
4894226 |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
A pharmaceutical composition is prepared wherein a biologically active conjugated protein is dissolved in an aqueous carrier medium in the absence of a solubilizing agent. The unconjugated protein,...
|
|
|
4894330 |
Purification of recombinant beta-interferon incorporating RP-HPLC
Improved RP-HPLC methods for purifying recombinant betainterferon are disclosed. Said RP-HPLC methods employ wide pore silica gel reverse-phase columns and solvent systems containing acetonitrile...
|
|
|
4885164 |
Aqueous protein solutions stable to denaturation
What are disclosed are a method for preventing the denaturation of proteins such as insulin in aqueous solution at interfaces by the addition to the solution of a surface-active substance...
|
|
|
4883661 |
Use of arginine as an lymphokine synergist
It has been found that arginine serves to increase the receptivity of cells to lymphokines such as interleukin-2 and interferon. An improved method for treating a mammal with one or more...
|
|
|
4865841 |
Methods and compositions for transient elimination of humoral immune antibodies
Antibody is removed from the blood of patients who are being treated or diagnosed with exogenous macromolecules, such as immunotoxins. As the immunotoxins are foreign antigens, the patient will...
|
|
|
4857316 |
Synergistic antiviral composition
Combinations of 9-(1,3-dihydroxy-2-propoxymethyl) guanine or a pharmaceutically acceptable salt thereof, with β-interferon show a surprisingly high degree of synergism in their activity against...
|
|
|
4857315 |
Compositions containing golgi alpha-mannosidase II inhibitors
The invention relates to compositions containing an inhibitor of the Golgi enzyme α-mannosidase II and which may contain an interferon or interferon inducer and to methods of preventing and...
|
|
|
4851219 |
Method for the treatment of chronic myelogenous leukemia
Gamma interferon is employed in the treatment of chronic myelogenous leukemia. Patients treated in the benign stage exhibit partial and, in some cases, complete responses to gamma interferon....
|
|
|
4824432 |
Method for treating AIDS and other immune deficiencies and immune disorders
Methods are provided for the treatment of pathological conditions connected with the production of interferons which destroy the immune system and possess damaging action on the cell system of...
|
|
|
4816440 |
Stable formulation of biologically active proteins for parenteral injection
A pharmaceutical composition containing IL-2 or IFN-β dissolved in a suitable carrier medium at pH 7.0 to 8.0 stabilized with sodium laurate is suitable for parenteral injection into humans or...
|
|
|
4808523 |
Constitutive production of human IFN-β1 by mammalian cells transformed by the IFN-β1 gene fused to an SV40 early promoter
The invention concerns the production of the human fibroblast interferon, IFN-β1 by cells of mammalian origin which are capable of constitutively expressing a DNA sequence encoding for IFN-β1,...
|
|
|
4793995 |
Modified (1-56) beta interferons
Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 56 are described. These modified beta interferons exhibit changes in the antiviral, cell growth...
|